Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabidiol in Lennox-Gastaut Syndrome
NCT02224690Phase 3Completed
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Apr 2015
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial in Lennox-Gastaut syndrome (LGS) comparing Epidiolex 20 mg/kg/day with Placebo (2 arms). Primary endpoint: Percentage Change From Baseline In Drop Seizure Frequency During The Treatment Period at 14 weeks. Started Apr 2015; status: completed.
02
Drugs
cannabidiol
03
Conditions
Lennox-Gastaut syndrome (LGS)
Beyond the preview
Go deeper on NCT02224690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02224690.